[
  {
    "ts": null,
    "headline": "GSK resolves patent lawsuit against Pfizer over RSV vaccines",
    "summary": "(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK's patent rights in its competing RSV shot Arexvy, according to a Thursday filing in Delaware federal court.  GSK and Pfizer said in the filing that they would dismiss the case with prejudice, which means it cannot be refiled.  GSK, Pfizer and Moderna have developed RSV shots approved by the U.S. Food and Drug Administration, with GSK's Arexvy responsible for the majority of U.S. RSV vaccine sales.",
    "url": "https://finnhub.io/api/news?id=78e310bd88e831ccc6fa5832e6f17c0edcc44a284e07face0cf7954e8ff0da22",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743717797,
      "headline": "GSK resolves patent lawsuit against Pfizer over RSV vaccines",
      "id": 133704836,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK's patent rights in its competing RSV shot Arexvy, according to a Thursday filing in Delaware federal court.  GSK and Pfizer said in the filing that they would dismiss the case with prejudice, which means it cannot be refiled.  GSK, Pfizer and Moderna have developed RSV shots approved by the U.S. Food and Drug Administration, with GSK's Arexvy responsible for the majority of U.S. RSV vaccine sales.",
      "url": "https://finnhub.io/api/news?id=78e310bd88e831ccc6fa5832e6f17c0edcc44a284e07face0cf7954e8ff0da22"
    }
  },
  {
    "ts": null,
    "headline": "Potatoes, discount chains and drugmakers offer havens in stock-market bloodbath",
    "summary": "Potatoes, discount chains and drugmakers offer havens in stock-market bloodbath",
    "url": "https://finnhub.io/api/news?id=f57ab0882a5b1d37612cb12eb44e395004096d9025d533fa7641bd6e86d9b6ca",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743705780,
      "headline": "Potatoes, discount chains and drugmakers offer havens in stock-market bloodbath",
      "id": 133705356,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Potatoes, discount chains and drugmakers offer havens in stock-market bloodbath",
      "url": "https://finnhub.io/api/news?id=f57ab0882a5b1d37612cb12eb44e395004096d9025d533fa7641bd6e86d9b6ca"
    }
  },
  {
    "ts": null,
    "headline": "Centessa Pharmaceuticals: Smooth Move To New Programs, But Questions Remain",
    "summary": "Centessa Pharmaceuticals plc shifts focus to ORX750 for sleep disorders after discontinuing SerpinPC. Click here to find out why CNTA stock is a Hold.",
    "url": "https://finnhub.io/api/news?id=218442d63e8a91790957dfa5bbc5a38184ac0195db2bc5bcf9d0a1d162af4368",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743696510,
      "headline": "Centessa Pharmaceuticals: Smooth Move To New Programs, But Questions Remain",
      "id": 133699859,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2149256979/image_2149256979.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Centessa Pharmaceuticals plc shifts focus to ORX750 for sleep disorders after discontinuing SerpinPC. Click here to find out why CNTA stock is a Hold.",
      "url": "https://finnhub.io/api/news?id=218442d63e8a91790957dfa5bbc5a38184ac0195db2bc5bcf9d0a1d162af4368"
    }
  },
  {
    "ts": null,
    "headline": "JNJ vs. PFE: Which Drug Giant is a Better Buy Now?",
    "summary": "Both JNJ & PFE expect their sales and profits to improve in 2025.",
    "url": "https://finnhub.io/api/news?id=577f8440ee8c4800f3fbc99d3e2c2f84078fbcc5869748e44935a4ea9da8042e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743688740,
      "headline": "JNJ vs. PFE: Which Drug Giant is a Better Buy Now?",
      "id": 133697705,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Both JNJ & PFE expect their sales and profits to improve in 2025.",
      "url": "https://finnhub.io/api/news?id=577f8440ee8c4800f3fbc99d3e2c2f84078fbcc5869748e44935a4ea9da8042e"
    }
  },
  {
    "ts": null,
    "headline": "GoodRx launches new e-commerce experience for prescriptions",
    "summary": "GoodRx is trying to help pharmacies compete in a digital age, where they already face pressure on their margins.",
    "url": "https://finnhub.io/api/news?id=5bbff504d35469e77cc16b8c9367a57414d42d1db7287593f97b4540694681bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743685244,
      "headline": "GoodRx launches new e-commerce experience for prescriptions",
      "id": 133697613,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "GoodRx is trying to help pharmacies compete in a digital age, where they already face pressure on their margins.",
      "url": "https://finnhub.io/api/news?id=5bbff504d35469e77cc16b8c9367a57414d42d1db7287593f97b4540694681bf"
    }
  },
  {
    "ts": null,
    "headline": "Better Beaten-Down Stock to Buy: Pfizer Vs. Moderna",
    "summary": "In 2020, many companies tried to develop effective coronavirus vaccines, but two ended up succeeding and dominating the field: Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA).  If Pfizer and Moderna can bounce back, purchasing their shares now might be a great move -- but which is the more attractive option?  Pfizer has made important moves in the past few years that could pay off down the line.",
    "url": "https://finnhub.io/api/news?id=29d32d85bc67231ca2e8c35213479ad89c7a010cf362fbcf56839b7552f1802a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743683400,
      "headline": "Better Beaten-Down Stock to Buy: Pfizer Vs. Moderna",
      "id": 133697787,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "In 2020, many companies tried to develop effective coronavirus vaccines, but two ended up succeeding and dominating the field: Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA).  If Pfizer and Moderna can bounce back, purchasing their shares now might be a great move -- but which is the more attractive option?  Pfizer has made important moves in the past few years that could pay off down the line.",
      "url": "https://finnhub.io/api/news?id=29d32d85bc67231ca2e8c35213479ad89c7a010cf362fbcf56839b7552f1802a"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer Stock a Buy?",
    "summary": "Pfizer's (NYSE: PFE) share price has fallen more than the S&P 500 so far this year.  If you're a growth investor, you probably won't be interested in buying Pfizer stock.  Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb.",
    "url": "https://finnhub.io/api/news?id=8e3c2467711da35b0f34d56dc713f78d3db49b17a9196dfff1b84836603ddcdf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743673620,
      "headline": "Is Pfizer Stock a Buy?",
      "id": 133697788,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer's (NYSE: PFE) share price has fallen more than the S&P 500 so far this year.  If you're a growth investor, you probably won't be interested in buying Pfizer stock.  Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb.",
      "url": "https://finnhub.io/api/news?id=8e3c2467711da35b0f34d56dc713f78d3db49b17a9196dfff1b84836603ddcdf"
    }
  },
  {
    "ts": null,
    "headline": "2 Absurdly Cheap Stocks to Buy and Hold for Years",
    "summary": "Buying stock in great companies when they are dealing with some short-term issue that creates stock price weakness can set investors up for big gains down the road.  As long as the business is still in good shape, adding it to your portfolio when it's trading at a sizable discount can look like a brilliant move in the future.  Stocks normally trade at discounts when there are concerns or question marks about the company's future performance.",
    "url": "https://finnhub.io/api/news?id=b0bc3de52a55b7773eb5dc6856800436615f22d8e37d7b353a60b6dc9bdd4b8c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743669600,
      "headline": "2 Absurdly Cheap Stocks to Buy and Hold for Years",
      "id": 133697789,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Buying stock in great companies when they are dealing with some short-term issue that creates stock price weakness can set investors up for big gains down the road.  As long as the business is still in good shape, adding it to your portfolio when it's trading at a sizable discount can look like a brilliant move in the future.  Stocks normally trade at discounts when there are concerns or question marks about the company's future performance.",
      "url": "https://finnhub.io/api/news?id=b0bc3de52a55b7773eb5dc6856800436615f22d8e37d7b353a60b6dc9bdd4b8c"
    }
  },
  {
    "ts": null,
    "headline": "A Historic Opportunity For Dividend Investors",
    "summary": "A Historic Opportunity For Dividend Investors",
    "url": "https://finnhub.io/api/news?id=9ee7826ec0f19b4b8a06d50ce418d4c88b6db69d77bfa2930d8f99683c73d32c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743667500,
      "headline": "A Historic Opportunity For Dividend Investors",
      "id": 133696452,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=9ee7826ec0f19b4b8a06d50ce418d4c88b6db69d77bfa2930d8f99683c73d32c"
    }
  }
]